

## Product datasheet for TL315486

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **GRO alpha (CXCL1) Human shRNA Plasmid Kit (Locus ID 2919)**

**Product data:** 

**Product Type:** shRNA Plasmids

**Product Name:** GRO alpha (CXCL1) Human shRNA Plasmid Kit (Locus ID 2919)

**Locus ID:** 2919

Synonyms: FSP; GRO1; GROa; MGSA; MGSA-a; NAP-3; SCYB1

Vector:pGFP-C-shLenti (TR30023)E. coli Selection:Chloramphenicol (34 ug/ml)

Mammalian Cell

Selection:

Puromycin

Format: Lentiviral plasmids

CXCL1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 2919).

5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.

RefSeq: NM 001511, NR 046035, NM 001511.1, NM 001511.2, NM 001511.3, BC011976, BC011976.1,

BM554448, BM996663, NM 001511.4

UniProt ID: P09341

**Summary:** This antimicrobial gene encodes a member of the CXC subfamily of chemokines. The

encoded protein is a secreted growth factor that signals through the G-protein coupled receptor, CXC receptor 2. This protein plays a role in inflammation and as a chemoattractant for neutrophils. Aberrant expression of this protein is associated with the growth and progression of certain tumors. A naturally occurring processed form of this protein has increased chemotactic activity. Alternate splicing results in coding and non-coding variants of this gene. A pseudogene of this gene is found on chromosome 4. [provided by RefSeq, Sep

2014]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







## Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).